Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 108.30M | 113.31M | 3.65M | 40.96M | 20.08M |
Gross Profit | 108.30M | 104.10M | -6.46M | -80.91M | -104.09M |
EBITDA | -101.74M | -58.79M | -152.61M | -117.18M | -143.39M |
Net Income | -97.01M | -57.51M | -161.82M | -122.25M | -149.91M |
Balance Sheet | |||||
Total Assets | 352.21M | 274.95M | 146.39M | 207.01M | 279.24M |
Cash, Cash Equivalents and Short-Term Investments | 302.08M | 200.35M | 88.50M | 150.56M | 184.50M |
Total Debt | 25.40M | 32.12M | 37.61M | 29.92M | 29.30M |
Total Liabilities | 142.69M | 235.32M | 191.48M | 174.51M | 196.46M |
Stockholders Equity | 209.51M | 39.63M | -45.09M | 32.50M | 82.78M |
Cash Flow | |||||
Free Cash Flow | -151.96M | -20.55M | -129.14M | -89.55M | -117.32M |
Operating Cash Flow | -151.03M | -19.43M | -127.78M | -88.99M | -115.98M |
Investing Cash Flow | -938.00K | -1.11M | -1.25M | -560.00K | -1.34M |
Financing Cash Flow | 253.89M | 132.53M | 67.19M | 55.83M | 154.54M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
58 Neutral | $1.30B | ― | -105.50% | ― | -7.06% | -57.17% | |
55 Neutral | $1.35B | ― | -49.41% | ― | 4.86% | 10.13% | |
48 Neutral | $814.01M | ― | -93.70% | ― | ― | -25.83% | |
46 Neutral | C$195.87M | -3.29 | -23.14% | 1.84% | 20.75% | -0.36% | |
43 Neutral | $1.30B | ― | -64.01% | ― | ― | 14.93% | |
42 Neutral | $789.78M | ― | -45.35% | ― | 22264.23% | 39.09% | |
31 Underperform | $1.11B | ― | -22.88% | ― | ― | 7.57% |
On May 8, 2025, Wave Life Sciences reported its first quarter financial results and provided a business update, highlighting significant progress in its clinical trials. The company completed dosing in the first two cohorts of its INLIGHT trial for obesity and advanced its RestorAATion-2 trial for alpha-1 antitrypsin deficiency. Additionally, Wave delivered positive data from its FORWARD-53 trial for Duchenne muscular dystrophy and plans to submit a new drug application in 2026. The company also announced a cash runway expected to last into 2027, reflecting its strong financial position.